An Investigation of the Past 10 Yrs Health Care for Primary Care Patients With Chronic Obstructive Pulmonary Disease

NCT01146392 | Completed

• 1 other identifier: NIS-RSE-DUM-2010/1
• Study Type: observational
• Target: 27,394
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to describe COPD health care and to assess demographics, concurrent diseases and mortality and the use of pharmaceuticals for a chronic obstructive pulmonary disease (COPD) population in real life in primary care during the last ten years.

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

Epidemiological; COPD health care; treatment in primary care

Outcome Measures

Primary Outcomes (1)

• Describe the development of COPD health care structure in primary care.

  Data will be extracted from the medical records on one occassion, covering a period of one decade.

Secondary Outcomes (1)

• Describe the COPD population in primary care with special reference to treatment, co-morbidity and mortality during last decade.

  Data will be extracted from the medical records on one occassion, covering a period of one decade.

Study Arms (1)

1

Primary care patients with COPD diagnosis

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Eligible subjects are all COPD patients, found in medical records at the participating swedish primary care clinics. Primarily patients with diagnosis code J44 (ICD-10) stated in the medical record will be investigated. Patient data from the period 1 January 1999 - 31 December 2009 will be included in the observation.

You may qualify if:

• COPD diagnosis according to medical records.
• Use of drugs prescribed for obstructive lung diseases

Sponsors & Collaborators

• AstraZeneca: lead

Study Sites (1)

Research Site

Uppsala, Sweden

Location

Related Publications (5)

• Larsson K, Janson C, Lisspers K, Jorgensen L, Stratelis G, Telg G, Stallberg B, Johansson G. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J Intern Med. 2013 Jun;273(6):584-94. doi: 10.1111/joim.12067. Epub 2013 Apr 1.

  PMID: 23495860 RESULT

• Stallberg B, Janson C, Johansson G, Larsson K, Stratelis G, Telg G, Lisspers KH. Management, morbidity and mortality of COPD during an 11-year period: an observational retrospective epidemiological register study in Sweden (PATHOS). Prim Care Respir J. 2014 Mar;23(1):38-45. doi: 10.4104/pcrj.2013.00106.

  PMID: 24346825 RESULT

• Sandelin M, Mindus S, Thuresson M, Lisspers K, Stallberg B, Johansson G, Larsson K, Janson C. Factors associated with lung cancer in COPD patients. Int J Chron Obstruct Pulmon Dis. 2018 Jun 6;13:1833-1839. doi: 10.2147/COPD.S162484. eCollection 2018.

  PMID: 29922050 DERIVED

• Lisspers K, Johansson G, Jansson C, Larsson K, Stratelis G, Hedegaard M, Stallberg B. Improvement in COPD management by access to asthma/COPD clinics in primary care: data from the observational PATHOS study. Respir Med. 2014 Sep;108(9):1345-54. doi: 10.1016/j.rmed.2014.06.002. Epub 2014 Jun 17.

  PMID: 25002194 DERIVED

• Janson C, Larsson K, Lisspers KH, Stallberg B, Stratelis G, Goike H, Jorgensen L, Johansson G. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ. 2013 May 29;346:f3306. doi: 10.1136/bmj.f3306.

  PMID: 23719639 DERIVED

Related Links

• Related Info
• CSR-NIS-RSE-DUM-2010-1.pdf
• NIS-RSE-DUM-2010/1 Clinical Report Synopsis

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Docent Gunnar Johansson

  Uppsala University, Sweden

  PRINCIPAL INVESTIGATOR

• Kjell Larsson, Prof

  Karolinska Institutet

  STUDY CHAIR

• Georgios Stratelis, MD

  AstraZeneca Nordics

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 16, 2010
• First Posted: June 17, 2010
• Study Start: June 1, 2010
• Primary Completion: September 1, 2011
• Study Completion: September 1, 2011
• Last Updated: June 18, 2014

Record last verified: 2014-06

Locations

SE (1)